RAC

1.11%

$1.83 race oncology ltd

RAC media coverage, page-2235

First 2235 Last

Share
Profile

Follow
KingBuzzo

350 Posts.

782

21/06/24

12:25

Post #: 74424231
Share

Originally posted by RaceOncology: ↑

There does appear to be differences is FTO variants between different human populations, but that does not matter for what we are doing in this trial. We are not measuring FTO activity directly, but the level of m6A in the RNA before and after treatment with bisantrene. We are looking to see if bisantrene changes the m6A in levels in RNA (we expect that it would increase), not inhibition of FTO directly.

The reason for this is it is the effect on m6A levels that matters, not if bisantrene directly inhibits FTO or not. You could imagine a scenario where bisantrene inhibits FTO, but the patient's cells compensate for this by decreasing the amount of METTL3 produced (i.e. decrease the amount of m6A methylation going on in the cell). If this were to happen then the level of m6A in the RNA might not change, or might even go down. Dynamic systems like the m6A regulatory system are very complex so it is important to measure what matters (m6A levels), not just intermediate effects upstream (i.e. FTO inhibition).

Of course this is just an exploratory first step to see if we can change the m6A levels in humans. If it is positive then we would look to do much more work in this and possibly look to run specific m6A trials where we expect this to have a significant therapeutic effect on the cancer the patient has. By doing things in careful steps we can maximise the return on our shareholders capital - I could spend $200m tomorrow on bisantrene studies, but I am not sure any of you would like the effect us raising $200m would have on the SP and your investment.

Expand

Does the FTO/m6A system function similarly in animals as it does in humans? If so has Race looked at Bisantrene's effect on m6A levels in any of the animal studies that have been performed? If not, why not?

In hindsight, we've heard lots about anti-cancer and cardio-protection results in animal studies but not much (actually, nothing that I can recall off the top of my head?) that directly addresses FTO/m6A levels. What are the reasons behind this?

Thank you in advance.

RAC Price at posting: $1.88 Sentiment: Buy Disclosure: Held
12 Upvote

1 Great analysis

Reply

Top Stories

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

RCE

Recce's R327 found effective against E.coli during clinical trial

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

CMX

ChemX Materials kicks off first stage works at WA high purity alumina pilot

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

AVA

Ava Risk Group expands US presence with A$0.7M Substation Deal

Microcap Wrap: 5 explorers with news out today

SVL

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

There are more pages in this discussion • 37 more messages in this thread...

First 2235 Last

Add RAC (ASX) to my watchlist

(20min delay)
Last $1.83		Change 0.020(1.11%)		Mkt cap ! $310.7M

Open	High	Low	Value	Volume
$1.81	$1.83	$1.79	$142.0K	78.77K

Buyers (Bids)

No.	Vol.	Price($)
1	500	$1.81

Sellers (Offers)

Price($)	Vol.	No.
$1.83	641	1

View Market Depth

No.	Vol.	Price($)
1	500	1.810
3	7009	1.790
1	450	1.780
2	16392	1.770
2	1018	1.765

Price($)	Vol.	No.
1.830	558	1
1.840	4000	2
1.845	2746	1
1.860	1000	1
1.870	1200	1

Last trade - 16.10pm 28/06/2024 (20 minute delay)

RAC (ASX) Chart

RAC media coverage, page-2235

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Recce's R327 found effective against E.coli during clinical trial

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Ava Risk Group expands US presence with A$0.7M Substation Deal

Microcap Wrap: 5 explorers with news out today

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

RAC media coverage, page-2235

Top Stories

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Recce's R327 found effective against E.coli during clinical trial

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Ava Risk Group expands US presence with A$0.7M Substation Deal

Microcap Wrap: 5 explorers with news out today

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News